Tuesday, August 9, 2011

CCO--Direct-Acting Antivirals in Treatment-Naive HCV Patients

New @ CCO
**Free registration required

Direct-Acting Antivirals in Treatment-Naive HCV Patients
Mark S. Sulkowski, MD, reviews the latest data on and the approved indications of telaprevir and boceprevir in treatment-naive, genotype 1 HCV–infected patients.

Learning Objectives
Upon completion of this activity, participants should be able to:
Outline the new standard of care of HCV protease inhibitor-based therapy for treatment-naïve genotype 1 HCV-infected patients
Apply findings from phase III clinical trials of boceprevir and telaprevir in treatment-naive patients with genotype 1 infection
Integrate the concept of response-guided therapy with boceprevir and telaprevir into clinical practice
Appraise strategies to manage adverse effects in patients receiving peginterferon/ribavirin plus either boceprevir or telaprevir
Provide accurate and appropriate counsel as part of the treatment team
Provide appropriate care and counsel for patients and their families

Clinical Options


No comments:

Post a Comment